Cash/Burn From SEC Filing For Period: 

Q3 '19

BHVN

Biohaven Pharmaceuticals

Biohaven is a clinical-stage biopharmaceutical company with proven leadership in industry and academic settings. Our portfolio is comprised of innovative, late-stage product candidates targeting neurological and neuropsychiatric diseases, including rare disorders.

Cash

$416.6M

Burn Rate

$276.9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Rimegepant

Acute Treatment of Migraine

Approved

Rimegepant

Migraine - preventative

sNDA/MAA Submission

TRORILUZOLE

Spinocerebellar Ataxia

Phase 3

1Q 2020

TRORILUZOLE

Generalized anxiety disorder (GAD)

Phase 3

BHV-3241

Multiple System Atrophy

Phase 3

4Q 2020

Vazegepant

Migraine - preventative

Phase 3 TBA

TRORILUZOLE

Alzheimer's Disease

Phase 2/3

4Q '20

TRORILUZOLE

Obsessive-Compulsive Disorder

Phase 2

4Q 2019

BHV-5000

Complex Regional Pain Syndrome

Phase 1

BHV-5000

Rett Syndrome

Phase 1

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon